Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 901371, 9 pages
Research Article

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma

1CNRS/UMR 6290/Biosit, Rennes 1 University, 35043 Rennes Cedex, France
2CHU Rennes, Department of Urology, 35033 Rennes, France
3Rennes University Hospital, 2 rue Henri Le Guilloux, 35033 Rennes Cedex, France
4CHU Rennes, Department of Nephrology, 35033 Rennes, France
5CHU Rennes, Department of Cytogenetics, 35033 Rennes, France
6Rennes 1 University, 35043 Rennes, France
7CHU Rennes, Department of Clinical Pharmacology, 35033 Rennes, France
8INSERM/Pharmacoepidemiology Team/CIC0203/Biosit, Rennes 1 University, 35043 Rennes, France
9CHU Rennes, Department of Biochemistry, 35033 Rennes, France
10CHU Rennes, Department of Pathology, 35033 Rennes, France

Received 27 February 2014; Accepted 25 April 2014; Published 22 May 2014

Academic Editor: Irfan A. Asangani

Copyright © 2014 Grégory Verhoest et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Angiotensin-2 type-1 receptor antagonists not are only antihypertensive drugs but also can inhibit VEGF production. We hypothesised that adding telmisartan to sunitinib could potentiate the antiangiogenic effects. Material and Methods. 786-O cell lines were injected in nude mice. After tumor development, mice were divided into 4 groups: the first was the control group (DMSO), the second group was treated with sunitinib alone, the third group was treated with telmisartan alone, and the fourth group was treated with the combination. Drugs were orally administered every day for four weeks. Animals were sacrificed after treatment. Blood and tumor tissues were collected for analysis by immunohistochemistry, Western Blot, and ELISA methods. Results. All animals developed a ccRCC and ten in each group were treated. Using a kinetic model, tumors tended to grow slower in the combination group compared to others (). Compared to sunitinib alone, the addition of telmisartan significantly increased tissue necrosis (). Central microvascular density decreased () as well as circulating VEGF (). There was no significant variation in proliferation or apoptosis markers. Conclusion. The combination of sunitinib and telmisartan revealed an enhancement of the blockage of the VEGF pathway on renal tumor resulting in a decrease in neoangiogenesis and an increase in necrosis.